-PSMA-617 in Oligometastatic Hormone-Sensitive Prostate Cancer (BULLSEYE): Open-Label, Randomise

01 Apr 20264 min read0 viewsJournal Feed

GIST

177Lu-PSMA-617 showed promising response rates and delayed disease progression in patients with oligometastatic HSPC in this trial. In addition, most treatment-related adverse events were low grade.

Clinical Editorial

Summary

The Lancet Oncology published a clinical update in Oncology on 01 Apr 2026.

The item focuses on -PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

10.1016/S1470-2045(25)00762-4

Open Original Source More Feed Items

Related by Condition/Drug

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

CCNE1 Gain Defines a Therapy-Refractory Gastric Cancer Subtype

Oncology • 28 Apr 2026

ClinicalTrialsRelated by Conditionprostate cancer

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Oncology • 08 Apr 2026

ClinicalTrialsRelated by Conditionprostate cancer

A Phase Ib/II Open-Label Study Of AMO959 With 177Lu-PSMA-617 In Combination With An ARPI In PSMA

Oncology • 01 Apr 2026

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer

Oncology • 10 Apr 2026

Prostate MRI Beyond Diagnosis: Prognostic Value After Radical Prostatectomy

Oncology • 02 Apr 2026

Feed Metadata

Source

The Lancet Oncology